{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:21:35Z","timestamp":1707524495706},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,29]]},"DOI":"10.7759\/cureus.23627","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T20:58:37Z","timestamp":1648587517000},"source":"Crossref","is-referenced-by-count":0,"title":["Partial Response to Small Molecule Inhibition in a Case of Anaplastic Large Cell Lymphoma"],"prefix":"10.7759","author":[{"given":"Sarah","family":"Young","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirah","family":"Kuzu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Magill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Hajdenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.path.2019.03.013","article-title":"Histiocytic and dendritic cell neoplasms","volume":"12","author":"Pan Z","year":"2019","unstructured":"Pan Z, Xu ML. Histiocytic and dendritic cell neoplasms. Surg Pathol Clin. 2019, 12:805-29. 10.1016\/j.path.2019.03.013","journal-title":"Surg Pathol Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800346","article-title":"Histiocytic sarcoma: a study of five cases including the histiocyte marker CD163","volume":"18","author":"Vos JA","year":"2005","unstructured":"Vos JA, Abbondanzo SL, Barekman CL, Andriko JW, Miettinen M, Aguilera NS. Histiocytic sarcoma: a study of five cases including the histiocyte marker CD163. Mod Pathol. 2005, 18:693-704. 10.1038\/modpathol.3800346","journal-title":"Mod Pathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0913","article-title":"Diverse and targetable kinase alterations drive histiocytic neoplasms","volume":"6","author":"Diamond EL","year":"2016","unstructured":"Diamond EL, Durham BH, Haroche J, et al.. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016, 6:154-65. 10.1158\/2159-8290.CD-15-0913","journal-title":"Cancer Discov"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond EL","year":"2019","unstructured":"Diamond EL, Durham BH, Ulaner GA, et al.. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019, 567:521-4. 10.1038\/s41586-019-1012-y","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1321","article-title":"Targeting alterations in the RAF-MEK pathway","volume":"9","author":"Yaeger R","year":"2019","unstructured":"Yaeger R, Corcoran RB. Targeting alterations in the RAF-MEK pathway. Cancer Discov. 2019, 9:329-41. 10.1158\/2159-8290.CD-18-1321","journal-title":"Cancer Discov"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-567461","article-title":"The biology and management of systemic anaplastic large cell lymphoma","volume":"126","author":"Hapgood G","year":"2015","unstructured":"Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015, 126:17-25. 10.1182\/blood-2014-10-567461","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-99716-2_6","article-title":"Anaplastic large cell lymphoma: contemporary concepts and optimal management","volume":"176","author":"Shustov A","year":"2019","unstructured":"Shustov A, Soma L. Anaplastic large cell lymphoma: contemporary concepts and optimal management. Cancer Treat Res. 2019, 176:127-44. 10.1007\/978-3-319-99716-2_6","journal-title":"Cancer Treat Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage KJ","year":"2008","unstructured":"Savage KJ, Harris NL, Vose JM, et al.. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008, 111:5496-504. 10.1182\/blood-2008-01-134270","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz S","year":"2019","unstructured":"Horwitz S, O'Connor OA, Pro B, et al.. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019, 393:229-40. 10.1016\/S0140-6736(18)32984-2","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14503","article-title":"The heterogeneous landscape of ALK negative ALCL","volume":"8","author":"Mereu E","year":"2017","unstructured":"Mereu E, Pellegrino E, Scarf\u00f2 I, Inghirami G, Piva R. The heterogeneous landscape of ALK negative ALCL. Oncotarget. 2017, 8:18525-36. 10.18632\/oncotarget.14503","journal-title":"Oncotarget"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar ER","year":"2014","unstructured":"Parrilla Castellar ER, Jaffe ES, Said JW, et al.. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014, 124:1473-80. 10.1182\/blood-2014-04-571091","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-614503","article-title":"Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts","volume":"127","author":"Scarf\u00f2 I","year":"2016","unstructured":"Scarf\u00f2 I, Pellegrino E, Mereu E, et al.. Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. Blood. 2016, 127:221-32. 10.1182\/blood-2014-12-614503","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.006","article-title":"Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma","volume":"27","author":"Crescenzo R","year":"2015","unstructured":"Crescenzo R, Abate F, Lasorsa E, et al.. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015, 27:516-32. 10.1016\/j.ccell.2015.03.006","journal-title":"Cancer Cell"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70351-1","article-title":"Common misdiagnoses in lymphomas and avoidance strategies","volume":"11","author":"Chan JK","year":"2010","unstructured":"Chan JK, Kwong YL.. Common misdiagnoses in lymphomas and avoidance strategies. Lancet Oncol. 2010, 11:579-588. 10.1016\/S1470-2045(09)70351-1","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2013.10.001","article-title":"MEK in cancer and cancer therapy","volume":"141","author":"Neuzillet C","year":"2014","unstructured":"Neuzillet C, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E. MEK in cancer and cancer therapy. Pharmacol Ther. 2014, 141:160-71. 10.1016\/j.pharmthera.2013.10.001","journal-title":"Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3507","article-title":"MEK\/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival","volume":"102","author":"Zheng B","year":"2003","unstructured":"Zheng B, Fiumara P, Li YV, et al.. MEK\/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood. 2003, 102:1019-27. 10.1182\/blood-2002-11-3507","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","volume":"7","author":"van der Weyden CA","year":"2017","unstructured":"van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J. 2017, 7:e603. 10.1038\/bcj.2017.85","journal-title":"Blood Cancer J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0925","article-title":"JunB induced by constitutive CD30-extracellular signal-regulated kinase 1\/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma","volume":"65","author":"Watanabe M","year":"2005","unstructured":"Watanabe M, Sasaki M, Itoh K, et al.. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1\/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res. 2005, 65:7628-34. 10.1158\/0008-5472.CAN-05-0925","journal-title":"Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/90427-partial-response-to-small-molecule-inhibition-in-a-case-of-anaplastic-large-cell-lymphoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:22Z","timestamp":1707507382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/90427-partial-response-to-small-molecule-inhibition-in-a-case-of-anaplastic-large-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.23627","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,29]]}}}